Compare Cassava Sciences Inc (FLNA) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs KKR & Co Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while KKR & Co Inc trades at $100.8 (market cap $90.64B). The key difference: KKR & Co Inc is far larger — about 1705.7× Cassava Sciences Inc's market cap, and KKR & Co Inc pays a 0.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | KKR | |
|---|---|---|
Market Cap | $53.14M | $90.64B |
Sector | Health | Financials |
52-Week High | $4.64 | $152.16 |
52-Week Low | $1.09 | $83.88 |
Enterprise Value | -$33.43M | $16.16B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
KKR trades at $102.21, up 5.14% with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 2026, and the firm is expanding through joint ventures in renewable energy and acquisitions like EDF Power Solutions. Cash flow improved to $1.78B in 2025, though revenue dipped to $19.21B. The stock is near its 52-week high, with RSI indicating potential overbought conditions.
Outlook is positive with a consensus price target of $122.71, but risks include volatile cash flows and high debt. Growth drivers are strategic expansions and strong institutional backing, yet investors should monitor execution on recent deals and macroeconomic impacts on asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
